Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 7/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 7/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 7/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 4/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | BCDIN3D | Q7Z5W3 | 5/20 | 0.33 |
| ▸ | CDK1 | P06493 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1066069 | 0.90 | MAPK14 (0.48) | MAPK13MAPK12MAPK11MAPK14KCNH2 | |
| SCHEMBL4179781 | 0.84 | MAPK14 (0.58) | MAPK13MAPK12MAPK11MAPK14KCNH2 | |
| SCHEMBL13853014 | 0.84 | MAPK13 (0.38) | MAPK13MAPK12MAPK11MAPK14KCNH2 | |
| SCHEMBL4183318 | 0.83 | MAPK13 (0.35) | MAPK13MAPK12MAPK11MAPK14KCNH2 | |
| SCHEMBL4183313 | 0.83 | MAPK13 (0.36) | MAPK13MAPK12MAPK11MAPK14KCNH2 | |
| SCHEMBL4176175 | 0.83 | MAPK13 (0.41) | MAPK13MAPK12MAPK11MAPK14KCNH2 | |
| SCHEMBL1063681 | 0.81 | MAPK14 (0.48) | MAPK13MAPK12MAPK11MAPK14KCNH2 | |
| SCHEMBL1065696 | 0.81 | MAPK14 (0.50) | MAPK13MAPK12MAPK11MAPK14KCNH2 | |
| SCHEMBL10202435 | 0.80 | MAPK14 (0.43) | MAPK13MAPK12MAPK11MAPK14KCNH2 | |
| SCHEMBL10202440 | 0.80 | MAPK14 (0.47) | MAPK13MAPK12MAPK11MAPK14KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137550-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2009-05-28 | — | — | US | disclosed |
| US-20090137550-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2009-05-28 | — | — | US | disclosed |
| US-20090137550-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2009-05-28 | — | — | US | disclosed |
| US-20090005401-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2009-01-01 | — | — | US | disclosed |
| US-20090005401-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2009-01-01 | — | — | US | disclosed |
| US-20090005401-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2009-01-01 | — | — | US | disclosed |
| US-7423042-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-09 | — | — | US | disclosed |
| US-7423042-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-09 | — | — | US | disclosed |
| US-7423042-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-09 | — | — | US | disclosed |
| EP-1868612-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006110298-A2 | 8-ALKYL/ARYL-4-ARYL-2-N- (ALKYLAMINO)-N'-SUBSTITUTED-N'-CYANOGUANIDINO-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE COMPOUNDS AND USE THEREOF | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| US-20060217401-A1 | e.g. 8-Alkyl/Aryl-4-aryl-2-N-(alkylamino)-N''-substituted-N'-cyanoguanidino-8H-pyrido[2,3-d]pyrimidin-7-one compounds; CSBP/p38 kinase inhibitor; antiinflammatory agent; inflammatory bowel disease; tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, rheumatoid arthritis | GLAXO GROUP LIMITED (GB) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217401-A1 | e.g. 8-Alkyl/Aryl-4-aryl-2-N-(alkylamino)-N''-substituted-N'-cyanoguanidino-8H-pyrido[2,3-d]pyrimidin-7-one compounds; CSBP/p38 kinase inhibitor; antiinflammatory agent; inflammatory bowel disease; tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, rheumatoid arthritis | MAPK8, MAPKAPK2, MAPK7 | MAPK13 19/4885MAPK12 37/4885MAPK11 78/4885 |
| US-20090005401-A1 | Novel Compounds | MAPKAPK2, CREBBP, MAPK8 | MAPK13 51/4885MAPK12 39/4885MAPK11 77/4885 |
| US-20090137550-A1 | Novel Compounds | MAPKAPK2, CREBBP, MAPK8 | MAPK13 51/4885MAPK12 39/4885MAPK11 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.